A2 emerges with $57M series A, engineered T cells for solid tumors

A2 debuted Tuesday with a $57 million series A round and two T cell immunotherapy strategies for solid tumors. The Column Group led the tranched round, with participation by Vida Ventures, Samsara BioCapital and Nextech Invest.

A2 Biotherapeutics Inc.’s first therapeutic approach consists of CAR T cells against MHC-displayed neoantigens. In the second, the company directs T cells, which express engineered TCRs or CARs, to attack tumor cells based on missing targets, a consequence of chromosomal alterations. ...